A vast amount remains to be learned about PitNET pathogenesis in the setting of SDHx and MAX variants and particularly on the role of pseudohypoxic and kinase signalling pathways in pituitary disease, which may reveal novel biomarkers and medical therapies. This evidence concerns the gene MAX and pituitary gland disorder.